StockNews.com Downgrades Kura Oncology (NASDAQ:KURA) to Sell

Kura Oncology (NASDAQ:KURA) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.

A number of other brokerages have also recently commented on KURA. Wedbush restated an “outperform” rating and issued a $37.00 price target on shares of Kura Oncology in a research report on Monday, November 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a report on Wednesday, November 6th. HC Wainwright reiterated a “buy” rating and set a $32.00 price target on shares of Kura Oncology in a research report on Wednesday, November 13th. Lifesci Capital raised shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. Finally, UBS Group initiated coverage on Kura Oncology in a research note on Thursday, October 24th. They set a “buy” rating and a $27.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $28.83.

Kura Oncology Stock Down 0.5 %

NASDAQ KURA opened at $15.96 on Wednesday. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -6.76 and a beta of 0.86. The company has a 50 day moving average of $18.36 and a 200-day moving average of $19.85. Kura Oncology has a 1-year low of $9.06 and a 1-year high of $24.17.

Institutional Investors Weigh In On Kura Oncology

A number of hedge funds and other institutional investors have recently bought and sold shares of KURA. Avoro Capital Advisors LLC boosted its stake in shares of Kura Oncology by 29.2% during the first quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock valued at $82,120,000 after purchasing an additional 870,000 shares in the last quarter. Suvretta Capital Management LLC raised its holdings in Kura Oncology by 8.2% in the 3rd quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock valued at $149,535,000 after buying an additional 583,155 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in Kura Oncology by 50.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock worth $35,653,000 after buying an additional 577,732 shares during the period. Affinity Asset Advisors LLC grew its holdings in Kura Oncology by 281.4% during the 1st quarter. Affinity Asset Advisors LLC now owns 730,492 shares of the company’s stock worth $15,581,000 after acquiring an additional 538,957 shares during the last quarter. Finally, Sofinnova Investments Inc. increased its position in Kura Oncology by 64.4% in the 2nd quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock valued at $16,992,000 after acquiring an additional 323,303 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.